公开(公告)号：US06300118B1

公开(公告)日：2001-10-09

申请号：US08479703

申请日：1995-06-07

Applicant: Lloyd Chavez ,  Terri Wasmoen ,  Chengjin Huang

Inventor： Lloyd Chavez ,  Terri Wasmoen ,  Chengjin Huang

IPC: C12N1563

CPC classification number: C12N15/8509 ,  A01K2217/05 ,  A01K2227/10 ,  A01K2267/01 ,  A01K2267/0337 ,  A61K39/00 ,  C07K14/005 ,  C12N2740/15022

Abstract: The present invention pertains to the prevention or lessening of disease in cats caused by Feline Immunodeficiency Virus (FIV). Prevention or lessening of disease is understood to mean the amelioration of any symptoms, including immune system disruptions, that result from FIV infection. The invention provides for a plasmid which encodes the FIV genome where said genome has had a portion of the gag gene, specifically the p10 (nucleocapsid) coding region, or a portion thereof, deleted. This deletion prevents the production of functional or whole p10 protein, which in turn, prevents the packaging of RNA into virions produced from transfection of this plasmid into an appropriate host cell, resulting in virions which do not contain RNA. Such virions will be described as “empty” virions. The invention also encompasses host cells transformed with the plasmid which produce the empty virions, and the empty virions themselves. In another embodiment, the invention encompasses vaccines that comprise one or more empty virions described above, with a pharmaceutically acceptable carrier or diluent and a pharmaceutically acceptable adjuvant. In yet another aspect, the invention provides methods for preventing or lessening disease caused by FIV, which is carried out by administering to a feline in need of such treatment the vaccines described above.

Abstract translation: 本发明涉及由猫免疫缺陷病毒（FIV）引起的猫的疾病的预防或减轻。 理解疾病的预防或减轻意味着由FIV感染引起的任何症状（包括免疫系统中断）的改善。 本发明提供编码FIV基因组的质粒，其中所述基因组具有一部分gag基因，特别是p10（核衣壳）编码区或其部分缺失。 该缺失可防止功能性或整个p10蛋白的产生，这反过来又防止了将RNA包装在由该质粒转染到合适的宿主细胞中而产生的病毒颗粒中，导致不含有RNA的病毒粒子。 这样的病毒粒子将被描述为“空”病毒粒子。 本发明还包括用产生空病毒粒子的质粒转化的宿主细胞，以及空的病毒粒子本身。 在另一个实施方案中，本发明包括包含一种或多种如上所述的空病毒体与药学上可接受的载体或稀释剂和药学上可接受的佐剂的疫苗。 另一方面，本发明提供了预防或减轻由FIV引起的疾病的方法，其通过向需要这种治疗的猫科动物施用上述疫苗来进行。

公开(公告)号：US08685412B2

公开(公告)日：2014-04-01

申请号：US13226685

申请日：2011-09-07

Applicant: Chengjin Huang ,  Jennifer Hess

Inventor： Chengjin Huang ,  Jennifer Hess

IPC: A01N63/02 ,  A61K39/00 ,  A61K39/125 ,  C12N7/04

CPC classification number: C07K16/10 ,  A61K39/12 ,  A61K39/125 ,  A61K2039/552 ,  C12N7/00 ,  C12N2770/16034

Abstract: The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting felines against infection or preventing disease caused by feline calicivirus alone or in addition to other pathogens that comprises administering to the felines an immunologically effective amount of the monovalent and multivalent vaccines described herein. Also, the invention concerns methods for diagnosing or detecting the hemorrhagic feline calicivirus in a susceptible host, asymptomatic carrier and the like by detecting the presence of feline calicivirus FCV-DD1 or antibodies raised or produced against feline calicivirus FCV-DD1 antigen.

Abstract translation: 本发明涉及一种新颖的分离纯化的出血性杯状病毒FCV-DD1。 本发明还包括含有新的FCV-DD1菌株的单价和多价疫苗。 此外，本发明包括保护猫科动物免受感染或预防单独的猫杯状病毒病引起的疾病或除了其它病原体之外的疾病的方法，其包括给予猫科动物免疫有效量的本文所述的单价和多价疫苗。 此外，本发明涉及通过检测猫杯状病毒FCV-DD1或针对猫杯状病毒FCV-DD1抗原产生或产生的抗体的存在来诊断或检测易感宿主中无出血性猫杯状病毒的方法，无症状载体等。

公开(公告)号：US07306807B2

公开(公告)日：2007-12-11

申请号：US11223099

申请日：2005-09-09

Applicant: Chengjin Huang ,  Jennifer Hess

Inventor： Chengjin Huang ,  Jennifer Hess

IPC: A61K39/125 ,  A61K39/395 ,  A61K39/42 ,  A61B5/055 ,  C12Q1/70

CPC classification number: C07K16/10 ,  A61K39/12 ,  A61K39/125 ,  A61K2039/552 ,  C12N7/00 ,  C12N2770/16034

Abstract: The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting felines against infection or preventing disease caused by feline calicivirus alone or in addition to other pathogens that comprises administering to the felines an immunologically effective amount of the monovalent and multivalent vaccines described herein. Also, the invention concerns methods for diagnosing or detecting the hemorrhagic feline calicivirus in a susceptible host, asymptomatic carrier and the like by detecting the presence of feline calicivirus FCV-DD1 or antibodies raised or produced against feline calicivirus FCV-DD1 antigen.

Abstract translation: 本发明涉及一种新颖的分离纯化的出血性杯状病毒FCV-DD1。 本发明还包括含有新的FCV-DD1菌株的单价和多价疫苗。 此外，本发明包括保护猫科动物免受感染或预防单独的猫杯状病毒病引起的疾病或除了其它病原体之外的疾病的方法，其包括给予猫科动物免疫有效量的本文所述的单价和多价疫苗。 此外，本发明涉及通过检测猫杯状病毒FCV-DD1或针对猫杯状病毒FCV-DD1抗原产生或产生的抗体的存在来诊断或检测易感宿主中无出血性猫杯状病毒的方法，无症状载体等。

公开(公告)号：US20060057159A1

公开(公告)日：2006-03-16

申请号：US11223099

申请日：2005-09-09

Applicant: Chengjin Huang ,  Jennifer Hess

Inventor： Chengjin Huang ,  Jennifer Hess

IPC: A61K39/12 ,  C12N7/00

CPC classification number: C07K16/10 ,  A61K39/12 ,  A61K39/125 ,  A61K2039/552 ,  C12N7/00 ,  C12N2770/16034

Abstract: The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting felines against infection or preventing disease caused by feline calicivirus alone or in addition to other pathogens that comprises administering to the felines an immunologically effective amount of the monovalent and multivalent vaccines described herein. Also, the invention concerns methods for diagnosing or detecting the hemorrhagic feline calicivirus in a susceptible host, asymptomatic carrier and the like by detecting the presence of feline calicivirus FCV-DD1 or antibodies raised or produced against feline calicivirus FCV-DD1 antigen.

Abstract translation: 本发明涉及一种新颖的分离纯化的出血性杯状病毒FCV-DD1。 本发明还包括含有新的FCV-DD1菌株的单价和多价疫苗。 此外，本发明包括保护猫科动物免受感染或预防单独的猫杯状病毒病引起的疾病或除了其它病原体之外的疾病的方法，其包括给予猫科动物免疫有效量的本文所述的单价和多价疫苗。 此外，本发明涉及通过检测猫杯状病毒FCV-DD1或针对猫杯状病毒FCV-DD1抗原产生或产生的抗体的存在来诊断或检测易感宿主中无出血性猫杯状病毒的方法，无症状载体等。

公开(公告)号：US20110318383A1

公开(公告)日：2011-12-29

申请号：US13226685

申请日：2011-09-07

Applicant: Chengjin HUANG ,  Jennifer Hess

Inventor： Chengjin HUANG ,  Jennifer Hess

IPC: A61K39/295 ,  A61P31/12 ,  A61P37/04 ,  C12N7/00 ,  A61K39/125

CPC classification number: C07K16/10 ,  A61K39/12 ,  A61K39/125 ,  A61K2039/552 ,  C12N7/00 ,  C12N2770/16034

Abstract: The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting felines against infection or preventing disease caused by feline calicivirus alone or in addition to other pathogens that comprises administering to the felines an immunologically effective amount of the monovalent and multivalent vaccines described herein. Also, the invention concerns methods for diagnosing or detecting the hemorrhagic feline calicivirus in a susceptible host, asymptomatic carrier and the like by detecting the presence of feline calicivirus FCV-DD1 or antibodies raised or produced against feline calicivirus FCV-DDI antigen.

Abstract translation: 本发明涉及一种新颖的分离纯化的出血性杯状病毒FCV-DD1。 本发明还包括含有新的FCV-DD1菌株的单价和多价疫苗。 此外，本发明包括保护猫科动物免受感染或预防单独的猫杯状病毒病引起的疾病或除了其它病原体之外的疾病的方法，其包括给予猫科动物免疫有效量的本文所述的单价和多价疫苗。 此外，本发明涉及通过检测猫杯状病毒FCV-DD1或针对猫杯状病毒FCV-DDI抗原产生或产生的抗体的存在来诊断或检测易感宿主中无出血性猫杯状病毒的方法，无症状载体等。

公开(公告)号：US07396660B2

公开(公告)日：2008-07-08

申请号：US10844716

申请日：2004-05-13

Applicant: Chengjin Huang ,  Deborah T. Chaleff ,  Mark E. Ruppen ,  Jerome Stephens

Inventor： Chengjin Huang ,  Deborah T. Chaleff ,  Mark E. Ruppen ,  Jerome Stephens

IPC: C12P19/44 ,  C12N15/52 ,  C12N15/70 ,  C12N15/76

CPC classification number: C12N9/0004 ,  C12N9/1007 ,  C12N9/16 ,  C12N15/52 ,  C12P17/181

Abstract: The present invention relates to the complete biosynthetic pathway for the formation of the LL-F28249 compounds and, most importantly, the major component LL-F28249α. The purified and isolated nucleic acid molecule encoding the proteins of the biosynthetic pathway, which is isolated from a wild-type or mutant Streptomyces, is fully described in FIG. 6 to FIG. 6-39 and SEQ ID NO:1. The DNA gene cluster and its expression in a suitable host enable the efficient production of the highly active natural metabolites and semisynthetic derivatives. The invention further concerns plasmids, vectors and host cells that contain and express the novel nucleic acid molecule. Of particular interest, the entire biosynthetic pathway fits compactly in three plasmids, Cos11, Cos36 and Cos40. The invention also concerns the purified and isolated biosynthesis proteins that are encoded by the whole DNA gene cluster. Additionally, the invention involves a new efficient, biochemical method of preparing moxidectin.

Abstract translation: 本发明涉及用于形成LL-F28249化合物的完整生物合成途径，最重要的是涉及主要成分LL-F28249α。 编码从野生型或突变链霉菌分离的生物合成途径的蛋白质的纯化和分离的核酸分子在图1中完全描述。 参照图6〜 6-39和SEQ ID NO：1。 DNA基因簇及其在合适的宿主中的表达使得能够高效生产高活性的天然代谢物和半合成衍生物。 本发明还涉及含有和表达新型核酸分子的质粒，载体和宿主细胞。 特别令人感兴趣的是，整个生物合成途径紧密地适应于三种质粒Cos11，Cos36和Cos40。 本发明还涉及由整个DNA基因簇编码的纯化和分离的生物合成蛋白。 此外，本发明涉及制备莫昔克丁的新的有效的生物化学方法。

公开(公告)号：US20080124359A1

公开(公告)日：2008-05-29

申请号：US11985696

申请日：2007-11-16

Applicant: Chengjin Huang ,  Jennifer Hess

Inventor： Chengjin Huang ,  Jennifer Hess

IPC: A61K39/125 ,  C07K16/08 ,  C12Q1/70

CPC classification number: C07K16/10 ,  A61K39/12 ,  A61K39/125 ,  A61K2039/552 ,  C12N7/00 ,  C12N2770/16034

Abstract: The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting felines against infection or preventing disease caused by feline calicivirus alone or in addition to other pathogens that comprises administering to the felines an immunologically effective amount of the monovalent and multivalent vaccines described herein. Also, the invention concerns methods for diagnosing or detecting the hemorrhagic feline calicivirus in a susceptible host, asymptomatic carrier and the like by detecting the presence of feline calicivirus FCV-DD1 or antibodies raised or produced against feline calicivirus FCV-DD1 antigen.

Abstract translation: 本发明涉及一种新颖的分离纯化的出血性杯状病毒FCV-DD1。 本发明还包括含有新的FCV-DD1菌株的单价和多价疫苗。 此外，本发明包括保护猫科动物免受感染或预防单独的猫杯状病毒病引起的疾病或除了其它病原体之外的疾病的方法，其包括给予猫科动物免疫有效量的本文所述的单价和多价疫苗。 此外，本发明涉及通过检测猫杯状病毒FCV-DD1或针对猫杯状病毒FCV-DD1抗原产生或产生的抗体的存在来诊断或检测易感宿主中无出血性猫杯状病毒的方法，无症状载体等。

公开(公告)号：US20090176969A1

公开(公告)日：2009-07-09

申请号：US12053013

申请日：2008-03-21

Applicant: Chengjin Huang ,  Deborah T. Chaleff ,  Mark E. Ruppen ,  Jerome Stephens

Inventor： Chengjin Huang ,  Deborah T. Chaleff ,  Mark E. Ruppen ,  Jerome Stephens

IPC: C07K14/195 ,  C12N15/31 ,  C12N15/70 ,  C12N1/21 ,  C12P21/02 ,  C12N15/75 ,  C12N15/76 ,  C12N15/77

CPC classification number: C12N9/0004 ,  C12N9/1007 ,  C12N9/16 ,  C12N15/52 ,  C12P17/181

Abstract: The present invention relates to the complete biosynthetic pathway for the formation of the LL-F28249 compounds and, most importantly, the major component LL-F28249α. The purified and isolated nucleic acid molecule encoding the proteins of the biosynthetic pathway, which is isolated from a wild-type or mutant Streptomyces, is fully described in FIG. 6 to FIG. 6-39 and SEQ ID NO:1. The DNA gene cluster and its expression in a suitable host enable the efficient production of the highly active natural metabolites and semisynthetic derivatives. The invention further concerns plasmids, vectors and host cells that contain and express the novel nucleic acid molecule. Of particular interest, the entire biosynthetic pathway fits compactly in three plasmids, Cos11, Cos36 and Cos40. The invention also concerns the purified and isolated biosynthesis proteins that are encoded by the whole DNA gene cluster. Additionally, the invention involves a new efficient, biochemical method of preparing moxidectin.

Abstract translation: 本发明涉及用于形成LL-F28249化合物的完整生物合成途径，最重要的是涉及主要成分LL-F28249α。 编码从野生型或突变链霉菌分离的生物合成途径的蛋白质的纯化和分离的核酸分子在图1中完全描述。 参照图6〜 6-39和SEQ ID NO：1。 DNA基因簇及其在合适的宿主中的表达使得能够高效生产高活性的天然代谢物和半合成衍生物。 本发明还涉及含有和表达新型核酸分子的质粒，载体和宿主细胞。 特别令人感兴趣的是，整个生物合成途径紧密地适应于三种质粒Cos11，Cos36和Cos40。 本发明还涉及由整个DNA基因簇编码的纯化和分离的生物合成蛋白。 此外，本发明涉及制备莫昔克丁的新的有效的生物化学方法。

公开(公告)号：US20050003409A1

公开(公告)日：2005-01-06

申请号：US10844716

申请日：2004-05-13

Applicant: Chengjin Huang ,  Deborah Chaleff ,  Mark Ruppen ,  Jerome Stephens

Inventor： Chengjin Huang ,  Deborah Chaleff ,  Mark Ruppen ,  Jerome Stephens

IPC: C12N15/09 ,  A61K31/7048 ,  A61P31/04 ,  C12N1/21 ,  C12N9/02 ,  C12N9/10 ,  C12N9/16 ,  C12N15/31 ,  C12N15/52 ,  C12N15/53 ,  C12N15/54 ,  C12N15/55 ,  C12P17/18 ,  C12R1/465 ,  C12Q1/68 ,  C07H21/04 ,  C12N9/88 ,  C12N15/74 ,  C12P19/60

CPC classification number: C12N9/0004 ,  C12N9/1007 ,  C12N9/16 ,  C12N15/52 ,  C12P17/181

Abstract: The present invention relates to the complete biosynthetic pathway for the formation of the LL-F28249 compounds and, most importantly, the major component LL-F28249α. The purified and isolated nucleic acid molecule encoding the proteins of the biosynthetic pathway, which is isolated from a wild-type or mutant Streptomyces, is fully described in FIG. 6 to FIG. 6-39and SEQ ID NO:1. The DNA gene cluster and its expression in a suitable host enable the efficient production of the highly active natural metabolites and semisynthetic derivatives. The invention further concerns plasmids, vectors and host cells that contain and express the novel nucleic acid molecule. Of particular interest, the entire biosynthetic pathway fits compactly in three plasmids, Cos11, Cos36 and Cos40. The invention also concerns the purified and isolated biosynthesis proteins that are encoded by the whole DNA gene cluster. Additionally, the invention involves a new efficient, biochemical method of preparing moxidectin.

Abstract translation: 本发明涉及用于形成LL-F28249化合物的完整生物合成途径，最重要的是涉及主要成分LL-F28249α。 编码从野生型或突变链霉菌分离的生物合成途径的蛋白质的纯化和分离的核酸分子在图1中完全描述。 参照图6〜 6-39和SEQ ID NO：1。 DNA基因簇及其在合适的宿主中的表达使得能够高效生产高活性的天然代谢物和半合成衍生物。 本发明还涉及含有和表达新型核酸分子的质粒，载体和宿主细胞。 特别令人感兴趣的是，整个生物合成途径紧密地适应于三种质粒Cos11，Cos36和Cos40。 本发明还涉及由整个DNA基因簇编码的纯化和分离的生物合成蛋白。 此外，本发明涉及制备莫昔克丁的新的有效的生物化学方法。